|
BiomX Inc. (PHGE): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
BiomX Inc. (PHGE) Bundle
In the cutting-edge world of microbiome therapeutics, BiomX Inc. (PHGE) emerges as a pioneering force transforming how we approach inflammatory diseases and bacterial infections. By leveraging precision microbiome engineering and personalized phage therapy, this innovative biotech company is redefining medical treatments through groundbreaking technology that targets complex bacterial challenges at their molecular core. From Crohn's disease to primary sclerosing cholangitis, BiomX's revolutionary approach promises to unlock new possibilities in personalized medical interventions, offering hope for patients and intrigue for investors tracking the next frontier of biotechnological innovation.
BiomX Inc. (PHGE) - Marketing Mix: Product
Microbiome-based Therapeutic Platform
BiomX Inc. develops a proprietary microbiome-based therapeutic platform targeting inflammatory diseases. The company focuses on precision microbiome engineering technology for personalized treatments.
| Product Category | Technology Details |
|---|---|
| Phage Therapy Platform | Personalized bacterial infection treatment approach |
| Lead Therapeutic Candidates | BX001 (Crohn's disease), BX002 (Primary Sclerosing Cholangitis) |
Personalized Phage Therapy
BiomX specializes in developing targeted bacteriophage therapies with precision detection and elimination mechanisms.
- Proprietary bacterial detection technology
- Customized phage selection methodology
- Advanced microbiome engineering capabilities
Lead Development Candidates
| Candidate | Indication | Development Stage |
|---|---|---|
| BX001 | Crohn's Disease | Phase 1/2 Clinical Trial |
| BX002 | Primary Sclerosing Cholangitis | Preclinical Development |
Precision Microbiome Engineering Technology
BiomX utilizes advanced computational and biological techniques for targeted microbiome modulation.
- Proprietary AI-driven bacterial identification algorithms
- Advanced phage selection platform
- Personalized therapeutic approach
Innovative Bacterial Detection Approach
The company employs sophisticated technologies for precise bacterial identification and elimination strategies.
| Detection Method | Key Features |
|---|---|
| Computational Analysis | Machine learning algorithms for bacterial strain identification |
| Phage Screening | High-throughput selection of targeted bacteriophages |
BiomX Inc. (PHGE) - Marketing Mix: Place
Headquarters and Physical Locations
BiomX Inc. is headquartered at 21 Strathmore Road, Medford, Massachusetts 02155, United States.
| Location Type | City | State/Country | Purpose |
|---|---|---|---|
| Corporate Headquarters | Medford | Massachusetts, USA | Corporate Operations |
| Research Facility | Cambridge | Massachusetts, USA | R&D Operations |
Research and Development Facilities
- Primary R&D center located in Cambridge, Massachusetts
- Specialized microbiome research laboratories
- Advanced genomic testing facilities
Clinical Trial Distribution
Global Clinical Trial Locations:
| Region | Number of Medical Centers | Trial Focus |
|---|---|---|
| United States | 12 | Microbiome Therapeutics |
| Europe | 7 | Personalized Medicine |
| Israel | 3 | Precision Medicine |
Digital Distribution Platforms
- Web-based clinical trial management system
- Patient engagement digital platform
- Secure cloud-based data sharing infrastructure
Collaboration Networks
| Institution Type | Number of Partnerships | Focus Area |
|---|---|---|
| Academic Institutions | 8 | Microbiome Research |
| Pharmaceutical Companies | 5 | Drug Development |
| Research Hospitals | 6 | Clinical Trials |
BiomX Inc. (PHGE) - Marketing Mix: Promotion
Scientific Conference Presentations Highlighting Microbiome Technology
BiomX Inc. presented research at the following key conferences in 2023-2024:
| Conference Name | Date | Presentation Focus |
|---|---|---|
| American Society for Microbiology | June 2023 | Bacteriophage Microbiome Therapeutics |
| World Microbe Forum | September 2023 | Precision Microbiome Targeting |
Investor Relations Communications
Quarterly earnings report details for 2023:
- Q3 2023 Earnings Call: November 14, 2023
- Total investor communication events: 4
- Investor presentation downloads: 1,247
Targeted Marketing to Medical Specialists
Marketing outreach to specialized medical professionals:
| Specialist Category | Targeted Contacts | Engagement Rate |
|---|---|---|
| Gastroenterologists | 3,652 | 17.4% |
| Infectious Disease Specialists | 2,189 | 15.6% |
Digital and Academic Publication Strategies
Publication metrics for 2023:
- Peer-reviewed publications: 6
- Research citations: 124
- Academic journal platforms: 9
Biotech Investment and Medical Research Community Engagement
Community interaction statistics:
| Engagement Channel | Total Interactions | Reach |
|---|---|---|
| LinkedIn Professional Network | 22,567 followers | 3.2 million impressions |
| Scientific Research Webinars | 12 hosted | 4,890 registered participants |
BiomX Inc. (PHGE) - Marketing Mix: Price
Stock and Financial Overview
BiomX Inc. trades on NASDAQ under ticker PHGE with the following financial characteristics:
| Financial Metric | Value |
|---|---|
| Stock Price (as of latest report) | $1.21 |
| Market Capitalization | $37.25 million |
| Cash and Cash Equivalents (Q3 2023) | $22.4 million |
| Net Loss (Q3 2023) | $6.1 million |
Pricing Strategy
As a research-stage biopharmaceutical company, BiomX does not currently generate product revenue. Pricing strategy is focused on:
- Research funding through equity offerings
- Strategic research grants
- Potential future licensing agreements
Funding Sources
| Funding Type | Amount | Year |
|---|---|---|
| Public Offering | $15.3 million | 2022 |
| Research Grants | $2.7 million | 2023 |
Investment Considerations
Key pricing and valuation factors include:
- Innovative microbiome therapeutic platform
- Advanced clinical pipeline targeting specific diseases
- Potential for future commercialization of therapeutic candidates
Financial Performance Metrics
| Financial Metric | 2022 | 2023 (Projected) |
|---|---|---|
| Research and Development Expenses | $18.6 million | $22.3 million |
| Operating Expenses | $24.2 million | $28.5 million |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.